Adverse events, compliance, and changes in therapy

被引：53

作者：

Düsing R. ^{[1
]}

机构：

[1] Medizinische Universitäts-Poliklinik, 53111 Bonn

来源：

Current Hypertension Reports | 2001年 / 3卷 / 6期

关键词：

Angiotensin Converting Enzyme Inhibitor; Antihypertensive Therapy; Medication Event Monitoring System; Dose History; Variable Compliance;

D O I：

10.1007/s11906-001-0011-0

中图分类号：

学科分类号：

摘要：

Compliance with medical therapy represents a multifacto-rial problem with marked consequences for individual and public health. Among the many contributing factors, the choice of drug may also determine the degree of compliance. Various studies investigating either compliance or persistence with antihypertensive therapy using a variety of methods have suggested that adherence to therapy may show the following pattern: diuretics < β-blockers < calcium channel blockers < ACE inhibitors. Furthermore, two recent studies have shown that therapy with angiotensin II receptor blockers may be associated with better long-term adherence than other antihypertensive monotherapies including angiotensin converting enzyme inhibitors. Since medication compliance with antihypertensive therapy, among other factors, closely correlates with the experience of side effects, it may be speculated that the different classes of antihypertensives may induce varying degrees of compliance and persistence due to their different tolerabil-ity profiles. Side effects may induce variable compliance and nonpersistence by yet another mechanism. Therapy turbulence, ie, any change in medication, is also associated with nonpersistence. Therefore, side effects may directly or indirectly (via inducing therapy turbulence) underly variable compliance and nonpersistence. Copyright © 2001 by Current Science Inc.

引用

页码：488 / 492

页数：4

共 22 条

[1] Haynes R.B., Introduction, Compliance in Health Care, pp. 1-7, (1979)
[2] Dusing R., Lottermoser K., Mengden T., Compliance with drug therapy - New answers to an old question, Nephrol Dial Transplant, 16, pp. 1317-1321, (2001)
[3] Kass M.A., Zimmermann T., Yablonski M., Compliance to pilocarpine therapy [abstract], Invest Ophthalmol, 108, (1977)
[4] Urquhardt J., The electronic medication event monitor. Lessons for pharmacotherapy, Clin Pharmacokinet, 32, pp. 345-356, (1997)
[5] Metry J.-M., Measuring compliance in clinical trials and ambulatory care, Drug Regimen Compliance. Issues in Clinical Trials and Patient Management, pp. 1-22, (1999)
[6] Urquhardt J., Role of patient compliance in clinical pharmacokinetics: Review of recent research, Clin Pharmacokinet, 27, pp. 202-215, (1994)
[7] Urquhart J., Chevalley C., Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals, Drug Information J, 22, pp. 363-378, (1988)
[8] Feinstein A., On white-coat effects and the electronic monitoring of compliance, Arch Intern Med, 150, pp. 1377-1378, (1990)
[9] Cramer J.A., Scheyer R.D., Mattson R.H., Compliance declines between clinic visits, Arch Intern Med, 150, pp. 1509-1510, (1990)
[10] Dusing R., Weisser B., Mengden T., Vetter H., Changes in antihypertensive therapy - The role of adverse effects and compliance, Blood Pres, 7, pp. 313-315, (1998)

← 1 2 3 →